Tradeherbal products and induction of cyp2c19 and cyp2e1 in cultured human hepatocytes

Basic and Clinical Pharmacology and Toxicology

Volumn 105, Issue 1, 2009, Pages 58-63

  Hellum, Bent H ^a,c   Hu, Zhuohan ^b   Nilsen, Odd Georg ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b FUDAN UNIVERSITY   (China)

^c Medical Technical Research Center Trondheim   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AESCULUS HIPPOCASTANUM EXTRACT; CHLORZOXAZONE; CYTOCHROME P450 2C19; CYTOCHROME P450 2E1; ECHINACEA PURPUREA EXTRACT; GINKGO BILOBA EXTRACT; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; MEPHENYTOIN; RIFAMPICIN; SALVIA OFFICINALIS EXTRACT; VALERIAN; CYP2C19 PROTEIN, HUMAN; PLANT EXTRACT; UNSPECIFIC MONOOXYGENASE;

ADULT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME SUBSTRATE; HERB DRUG INTERACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CULTURE; MALE; METABOLIC ACTIVATION; METABOLITE; PRIORITY JOURNAL; CELL CULTURE; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG EFFECT; ENZYMOLOGY; LIVER CELL; METABOLISM;

AESCULUS; GINKGO BILOBA; VALERIANA OFFICINALIS;

ARYL HYDROCARBON HYDROXYLASES; CELLS, CULTURED; CYTOCHROME P-450 CYP2E1; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPATOCYTES; HERB-DRUG INTERACTIONS; HUMANS; MALE; PLANT EXTRACTS;

EID: 67651208865     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2009.00412.x     Document Type: Article

References (30)

1. Raucy JL. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab Dispos 2003 May 31 : 533 9.
2. Hellum BH, Hu Z, Nilsen OG. The Induction of CYP1A2, CYP2D6 and CYP3A4 by Six Trade Herbal Products in Cultured Primary Human Hepatocytes. Basic Clin Pharmacol Toxicol 2007 Jan 100 : 23 30. (Pubitemid 46051439)
3. He N, Cai HB, Xie HG, Collins X, Edeki TI, Strom SC. Induction of cyp3a in primary cultures of human hepatocytes by ginkgolides a and B. Clin Exp Pharmacol Physiol 2007 Jul 34 : 632 5.
4. Indiana University Department of Medicine. P450 table. Internet 2007 November 29 ;cited 8 A.D. Aug 12 Available from: URL: http://medicine.iupui.edu/ flockhart/table.htm
5. Obach RS, Zhang QY, Dunbar D, Kaminsky LS. Metabolic characterization of the major human small intestinal cytochrome p450s. Drug Metab Dispos 2001 Mar 29 : 347 52.
6. Guengerich FP, Shimada T, Iwasaki M, Butler MA, Kadlubar FF. Activation of carcinogens by human liver cytochromes P-450. Basic Life Sci 1990 53 : 381 96.
7. Gorsky LD, Koop DR, Coon MJ. On the stoichiometry of the oxidase and monooxygenase reactions catalyzed by liver microsomal cytochrome P-450. Products of oxygen reduction. J Biol Chem 1984 Jun 10 259 : 6812 7.
8. Castillo T, Koop DR, Kamimura S, Triadafilopoulos G, Tsukamoto H. Role of cytochrome P-450 2E1 in ethanol-, carbon tetrachloride- and iron-dependent microsomal lipid peroxidation. Hepatology 1992 Oct 16 : 992 6.
9. Parkinson A. Biotransformation of Xenobiotics. In : Klaassen CD (ed.). Casarett and Doull's Toxicology: The Basic Science of Poisons, 5th edn. McGraw-Hill, New York, USA. 2001 113 86.
10. Fan L, Wang G, Wang LS, Chen Y, Zhang W, Huang YF et al. Herbal medicine yin zhi huang induces CYP3A4-mediated sulfoxidation and CYP2C19-dependent hydroxylation of omeprazole. Acta Pharmacol Sin 2007 Oct 28 : 1685 92.
11. Wang LS, Zhou G, Zhu B, Wu J, Wang JG, bd El-Aty AM et al. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther 2004 Mar 75 : 191 7.
12. Yin OQ, Tomlinson B, Waye MM, Chow AH, Chow MS. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics 2004 Dec 14 : 841 50.
13. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y et al. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging 2005 22 : 525 39.
14. Li AP, Roque MA, Beck DJ, Kaminski DL. Isolation and culturing of hepatocytes from human livers. Meth Cell Sci 1992 14 : 139 45.
15. Bardag-Gorce F, Li J, French BA, French SW. The effect of ethanol-induced CYP2E1 on proteasome activity: the role of 4-hydroxynonenal. Exp Mol Pathol 2005 Apr 78 : 109 15.
16. Lucas D, Ferrara R, Gonzalez E, Bodenez P, Albores A, Manno M et al. Chlorzoxazone, a selective probe for phenotyping CYP2E1 in humans. Pharmacogenetics 1999 Jun 9 : 377 88.
17. Wang LS, Zhu B, bd El-Aty AM, Zhou G, Li Z, Wu J et al. The influence of St John's Wort on CYP2C19 activity with respect to genotype. J Clin Pharmacol 2004 Jun 44 : 577 81.
18. Fourtillan JB, Brisson AM, Girault J, Ingrand I, Decourt JP, Drieu K et al. Pharmacokinetic properties of Bilobalide and Ginkgolides A and B in healthy subjects after intravenous and oral administration of Ginkgo biloba extract (EGb 761). Therapie 1995 Mar 50 : 137 44.
19. Kerb R, Brockmoller J, Staffeldt B, Ploch M, Roots I. Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin. Antimicrob Agents Chemother 1996 Sep 40 : 2087 93.
20. Bassler D, Okpanyi S, Schrodter A, Loew D, Schurer M, Schulz HU. Bioavailability of beta-aescin from horse chestnut seed extract: comparative clinical studies of two Galenic formulations. Adv Ther 2003 Sep 20 : 295 304. (Pubitemid 38101672)
21. Komoroski BJ, Zhang S, Cai H, Hutzler JM, Frye R, Tracy TS et al. Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos 2004 May 32 : 512 8.
22. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther 2005 May 77 : 415 26.
23. Uno T, Niioka T, Hayakari M, Yasui-Furukori N, Sugawara K, Tateishi T. Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations. Eur J Clin Pharmacol 2007 Feb 63 : 143 9.
24. Lapple F, von RO, Fromm MF, Richter T, Thon KP, Wisser H et al. Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics 2003 Sep 13 : 565 75.
25. Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, Daujat M, Waechter F, Fabre JM et al. Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos 2001 Mar 29 : 242 51.
26. Song BJ, Veech RL, Park SS, Gelboin HV, Gonzalez FJ. Induction of rat hepatic N-nitrosodimethylamine demethylase by acetone is due to protein stabilization. J Biol Chem 1989 Feb 25 264 : 3568 72.
27. Kupfer A, Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 1984 26 : 753 9.
28. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994 Oct 46 : 594 8.
29. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002 41 : 913 58.
30. Goldstein JA, Ishizaki T, Chiba K, De Morais SM, Bell D, Krahn PM et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997 Feb 7 : 59 64. (Pubitemid 27153320)